| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.97▼ | 0.97▼ | 0.99▼ | 1.01▼ | 1.10▼ |
| MA10 | 1.00▼ | 1.00▼ | 1.02▼ | 1.04▼ | 1.17▼ |
| MA20 | 1.02▼ | 1.03▼ | 1.03▼ | 1.11▼ | 1.27▼ |
| MA50 | 1.05▼ | 1.10▼ | 1.12▼ | 1.19▼ | 1.36▼ |
| MA100 | 1.13▼ | 1.18▼ | 1.23▼ | 1.29▼ | 1.54▼ |
| MA200 | 1.24▼ | 1.21▼ | 1.28▼ | 1.42▼ | 2.58▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.006▼ | -0.003▼ | -0.003▼ | -0.015▼ | -0.027▼ |
| RSI | 33.809▼ | 34.346▼ | 34.871▼ | 33.194▼ | 37.376▼ |
| STOCH | 13.878▼ | 22.827 | 19.987▼ | 16.095▼ | 16.346▼ |
| WILL %R | -88.692▼ | -88.692▼ | -89.196▼ | -89.053▼ | -94.734▼ |
| CCI | -79.872 | -90.711 | -105.469▼ | -120.205▼ | -143.242▼ |
| ▼ GAP | $MRKR Open Gap Down %2 | Set Alert |
|
Thursday, October 08, 2026 10:36 AM
Merck & Co. (NYSE:MRK) gets a higher price target as quarterly revenue tops forecasts and Keytruda keeps driving its healthcare growth story.
|
|
Thursday, October 08, 2026 05:30 AM
Merck (NYSE:MRK) reported FDA approval of WELIREG plus LENVIMA for adults with advanced renal cell carcinoma after prior PD-1/PD-L1 therapy. The approved combination involves WELIREG at 120 mg taken ...
|
|
Wednesday, October 07, 2026 07:01 AM
Merck (NYSE:MRK) steadies as pharma-administration pricing deals ease pressure, with Keytruda, vaccines and pipeline progress shaping the drugmaker's story.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 09/10/26 | 0.93 | 1.00 | 0.93 | 0.9716 | 91,220 |
| 08/10/26 | 1.04 | 1.05 | 0.95 | 0.95 | 96,404 |
| 07/10/26 | 1.03 | 1.06 | 1.03 | 1.04 | 36,853 |
| 06/10/26 | 1.07 | 1.07 | 1.00 | 1.01 | 77,100 |
| 05/10/26 | 1.08 | 1.085 | 1.045 | 1.06 | 73,138 |
| 02/10/26 | 1.06 | 1.08 | 1.02 | 1.05 | 99,289 |
| 01/10/26 | 1.08 | 1.09 | 0.981 | 1.05 | 127,494 |
| 30/09/26 | 1.12 | 1.14 | 1.07 | 1.07 | 38,387 |
| 29/09/26 | 1.14 | 1.16 | 1.075 | 1.10 | 90,886 |
| 28/09/26 | 1.12 | 1.15 | 1.07 | 1.125 | 164,335 |
|
|
||||
|
|
||||
|
|